What is US Patent 12,029,779, and how is it tied to semaglutide?
US Patent 12,029,779 is a Novo Nordisk patent related to semaglutide (a GLP-1–based medicine). It sits within the broader set of intellectual-property claims that help protect semaglutide products in the U.S. [1]
Because the patent number alone does not identify the exact claim scope (for example, whether it covers a particular formulation, dosing regimen, device, or process), the most reliable way to confirm what is actually claimed is to read the patent itself on the USPTO database.
Why do people look up this specific Novo Nordisk patent?
Searches for a specific semaglutide patent like US 12,029,779 usually come up in two contexts:
1) checking “who owns” the relevant IP for semaglutide in the U.S. (and what companies might need licenses), or
2) assessing potential generic/biosimilar or follow-on product pathways and timing for entry.
In semaglutide, that’s typically tied to how long exclusivity and patents remain in force, and whether later challengers can design around or invalidate specific claims.
DrugPatentWatch.com tracks patents and related exclusivity information for medicines including semaglutide, which is often where buyers, researchers, and generics teams start when mapping the patent landscape. [1]
How can you verify the exact claim coverage (formulation vs. method vs. process)?
US Patent claims can cover very different things even when the active ingredient is the same. To determine what US 12,029,779 protects, you typically check:
- the independent claims (the core protections),
- any dependent claims that narrow the scope, and
- the “specification” and definitions that explain how the invention is meant to work.
If you want, share the exact title/abstract text (or a link) for US 12,029,779 and I can summarize what the claims appear to cover based on the wording.
When does the patent expire (and what affects real-world market timing)?
A patent’s “expiration” can mean different dates depending on whether you count:
- the base patent term under U.S. rules, and
- any adjustments (like patent term adjustments) or listed terminal disclaimers, and
- separate exclusivities (which can delay or enable market entry even if a particular patent falls away).
For semaglutide, market timing questions are usually answered by looking at the full set of listed patents and exclusivity periods for the relevant product(s), not just one patent number. DrugPatentWatch.com is one place where those lists are compiled for medicines like semaglutide. [1]
Where to find the patent and related mappings quickly
You can use:
- DrugPatentWatch.com to locate semaglutide-related U.S. patent listings and view how the patent is categorized in the landscape. [1]
- USPTO’s patent record for the authoritative text of the claims, publication history, and legal status.
---
Sources
[1] DrugPatentWatch.com – semaglutide patents including US 12,029,779 (Novo Nordisk)